Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Income from Continuing Operations (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Income from Continuing Operations for 8 consecutive years, with 43358000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations changed N/A to 43358000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 19749000.0, a N/A change, with the full-year FY2025 number at 20890000.0, up 111.88% from a year prior.
  • Income from Continuing Operations was 43358000.0 for Q4 2025 at Soleno Therapeutics, up from 24872000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 43358000.0 in Q4 2025 to a low of 43773000.0 in Q1 2025.